Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 124

    1.

    Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.

    Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM.

    Genome Biol. 2001;2(10):RESEARCH0041. Epub 2001 Sep 13.

    PMID:
    11597333
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Transcriptional signature of flavopiridol-induced tumor cell death.

    Lü X, Burgan WE, Cerra MA, Chuang EY, Tsai MH, Tofilon PJ, Camphausen K.

    Mol Cancer Ther. 2004 Jul;3(7):861-72.

    PMID:
    15252147
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.

    Bonvini P, Zorzi E, Mussolin L, Monaco G, Pigazzi M, Basso G, Rosolen A.

    Haematologica. 2009 Jul;94(7):944-55. Epub 2009 Jun 16.

    PMID:
    19535344
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    4.

    Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.

    Raju U, Nakata E, Mason KA, Ang KK, Milas L.

    Cancer Res. 2003 Jun 15;63(12):3263-7.

    PMID:
    12810657
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.

    Senderowicz AM.

    Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S61-73. Epub 2003 Jun 18. Review.

    PMID:
    12819936
    [PubMed - indexed for MEDLINE]
    7.

    Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol.

    Smith V, Raynaud F, Workman P, Kelland LR.

    Mol Pharmacol. 2001 Nov;60(5):885-93.

    PMID:
    11641415
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.

    Chen R, Keating MJ, Gandhi V, Plunkett W.

    Blood. 2005 Oct 1;106(7):2513-9. Epub 2005 Jun 21.

    PMID:
    15972445
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.

    Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Yamaguchi H, Huang M, Jove R, Wang HG, Bhalla K.

    Cancer Res. 2003 Jan 1;63(1):93-9.

    PMID:
    12517783
    [PubMed - indexed for MEDLINE]
    Free Article
    11.
    12.

    Mechanisms of action of flavopiridol.

    Sedlacek HH.

    Crit Rev Oncol Hematol. 2001 May;38(2):139-70. Review.

    PMID:
    11311660
    [PubMed - indexed for MEDLINE]
    13.

    Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines.

    Honoki K, Yoshitani K, Tsujiuchi T, Mori T, Tsutsumi M, Morishita T, Takakura Y, Mii Y.

    Oncol Rep. 2004 May;11(5):1025-30.

    PMID:
    15069542
    [PubMed - indexed for MEDLINE]
    14.

    Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.

    Jaschke B, Milz S, Vogeser M, Michaelis C, Vorpahl M, Schömig A, Kastrati A, Wessely R.

    FASEB J. 2004 Aug;18(11):1285-7. Epub 2004 Jun 4.

    PMID:
    15180955
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity.

    Newcomb EW.

    Anticancer Drugs. 2004 Jun;15(5):411-9. Review.

    PMID:
    15166614
    [PubMed - indexed for MEDLINE]
    16.

    Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.

    Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B.

    Cancer Res. 2006 Dec 1;66(23):11389-98.

    PMID:
    17145885
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.

    Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Giménez MS, Dent P, Grant S.

    Mol Cancer Ther. 2007 Feb;6(2):692-702.

    PMID:
    17308065
    [PubMed - indexed for MEDLINE]
    Free Article
    18.

    Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.

    Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D, Ross DD.

    Clin Cancer Res. 2003 Aug 15;9(9):3320-8.

    PMID:
    12960118
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase.

    Matranga CB, Shapiro GI.

    Cancer Res. 2002 Mar 15;62(6):1707-17.

    PMID:
    11912144
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Rhabdoid tumor growth is inhibited by flavopiridol.

    Smith ME, Cimica V, Chinni S, Challagulla K, Mani S, Kalpana GV.

    Clin Cancer Res. 2008 Jan 15;14(2):523-32.

    PMID:
    18223228
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk